TR199902071T2 - Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m� - Google Patents

Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�

Info

Publication number
TR199902071T2
TR199902071T2 TR1999/02071T TR9902071T TR199902071T2 TR 199902071 T2 TR199902071 T2 TR 199902071T2 TR 1999/02071 T TR1999/02071 T TR 1999/02071T TR 9902071 T TR9902071 T TR 9902071T TR 199902071 T2 TR199902071 T2 TR 199902071T2
Authority
TR
Turkey
Prior art keywords
peptide
amylioid
inhibition
heterocyclic compounds
alzheimer
Prior art date
Application number
TR1999/02071T
Other languages
English (en)
Turkish (tr)
Inventor
D. Thorsett Eugene
J. Porter Warren
S. Nissen Jeffrey
H. Latimer Lee
E. Audia James
J. Droste James
Original Assignee
Elan Pharmaceuticals, Inc
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals, Inc, Eli Lilly & Company filed Critical Elan Pharmaceuticals, Inc
Publication of TR199902071T2 publication Critical patent/TR199902071T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TR1999/02071T 1997-02-28 1998-02-27 Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m� TR199902071T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80826397A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
TR199902071T2 true TR199902071T2 (xx) 2000-01-21

Family

ID=25198310

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02071T TR199902071T2 (xx) 1997-02-28 1998-02-27 Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�

Country Status (22)

Country Link
EP (1) EP0968198A1 (id)
JP (1) JP2001513107A (id)
KR (1) KR20000075767A (id)
CN (1) CN1253554A (id)
AR (1) AR011164A1 (id)
AU (1) AU6662298A (id)
BR (1) BR9807876A (id)
CA (1) CA2278674A1 (id)
CO (1) CO4920244A1 (id)
EA (1) EA199900778A1 (id)
HR (1) HRP980093A2 (id)
HU (1) HUP0001293A3 (id)
ID (1) ID22873A (id)
IL (1) IL130851A0 (id)
NO (1) NO994016L (id)
NZ (1) NZ336613A (id)
PE (1) PE59399A1 (id)
PL (1) PL335424A1 (id)
TR (1) TR199902071T2 (id)
WO (1) WO1998038177A1 (id)
YU (1) YU7998A (id)
ZA (1) ZA981627B (id)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
BR9812773A (pt) * 1997-12-22 2000-10-10 Elan Pharm Inc "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
WO2001010846A2 (en) * 1999-08-05 2001-02-15 Igt Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
DE10029077A1 (de) * 2000-06-13 2001-12-20 Bayer Ag Thiazolylsubstituierte Heterocyclen
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2840899B1 (fr) * 2002-06-12 2005-02-25 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
CA2486350A1 (en) 2002-06-05 2003-12-24 Kaneka Corporation Process for producing optically active .alpha.-methylcysteine derivative
EP1802303B1 (en) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
EP2081918A2 (en) 2006-10-03 2009-07-29 Array Biopharma, Inc. Mitotic kinesin inhibitors and methods of use thereof
EP2303847B1 (de) * 2008-07-16 2018-09-05 Bitop AG Synthese von zyklischen amidinen
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN103435549A (zh) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法
CN105646208B (zh) * 2016-02-24 2018-10-16 潍坊晶润化工股份有限公司 丙酮酸甲酯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof

Also Published As

Publication number Publication date
ZA981627B (en) 1999-10-05
KR20000075767A (ko) 2000-12-26
WO1998038177A1 (en) 1998-09-03
CN1253554A (zh) 2000-05-17
EP0968198A1 (en) 2000-01-05
HRP980093A2 (en) 1998-12-31
CA2278674A1 (en) 1998-09-03
CO4920244A1 (es) 2000-05-29
HUP0001293A1 (hu) 2000-08-28
PE59399A1 (es) 1999-06-21
BR9807876A (pt) 2000-02-29
ID22873A (id) 1999-12-16
AU6662298A (en) 1998-09-18
IL130851A0 (en) 2001-01-28
EA199900778A1 (ru) 2000-04-24
PL335424A1 (en) 2000-04-25
NO994016L (no) 1999-10-18
NO994016D0 (no) 1999-08-19
YU7998A (sh) 2002-06-19
NZ336613A (en) 2001-10-26
JP2001513107A (ja) 2001-08-28
AR011164A1 (es) 2000-08-02
HUP0001293A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
TR199902938T2 (xx) �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe eden bile�ikler ve y�ntemler.
TR199901343T2 (xx) Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
TR199901128T2 (xx) N-(aril/heteroarilasetil) amino asit esterler, bunu ihtiva eden farmas�tik bile�imler ve bu t�r bile�ikler kullanarak �-amiloit peptit sal�n�m�n� ve/veya bunun sentezlenmesini inhibe etme y�ntemleri.
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
DK0695758T3 (da) Pentapeptidamider og -estere til inhibering af human cancer
BG101841A (en) Cellular adhesion inhibitors
ES2188584T3 (es) Derivados heterociclicos de amina.
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BG106586A (en) Pyrazolopyramidines as therapeutic agents
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
GB0025173D0 (en) Therapeutic agents
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DK1147105T3 (da) Optisk aktivt pyridyl-4H-1,2,4-oxadiazinderivat og anvendelse af dette til behandling af karsygdomme
NO953072L (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
PE61999A1 (es) Compuestos de tetrahidropiridina
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.